Trial Profile
An Open-Label Study of Safety and Immunogenicity in Subjects Following Injection With Two Doses of HEPLISAV
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 May 2019
Price :
$35
*
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Dynavax Technologies
- 21 Jun 2010 Actual end date (Feb 2008) added as reported by ClinicalTrials.gov.
- 21 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Aug 2007 New trial record.